Announcements Trials
Browse Landscape

Phase

Phase 1 3Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 59Gastrointestinal 4Gynecologic 2Tumor-Agnostic 1Other solid neoplasm 1

Conditions

Solid Tumors 1

Interventions

Carboplatin 10Cisplatin 7Pemetrexed 6Vincristine 5Nivolumab 5Etoposide 4Topotecan 3Specimen Handling 3Ipilimumab 3Injections 3Doxorubicin 3Talc 2Radiotherapy 2Paclitaxel 2Granulocyte Colony-Stimulating Factor 2Gemcitabine 2Filgrastim 2Drug Therapy 2Cyclophosphamide 2tumor necrosis factor-alpha, CNGRC fusion protein, human 1sintilimab 1ranpirnase 1raltitrexed 1pertuzumab 1pembrolizumab 1onartuzumab 1iniparib 1durvalumab 1dostarlimab 1crofelemer 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × pertuzumab × Other solid neoplasm × Clear all
NCT02320435 2026-05-12

A Safety and Efficacy Extension Study of Pertuzumab in Patients With Solid Tumors Previously Enrolled in a Hoffmann-La Roche-Sponsored Pertuzumab Clinical Trial

Hoffmann-La Roche

Phase 3 Active not recruiting
154 enrolled
Other solid neoplasm

Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡